Allo-SCT is potentially curative for patients with AML. Patients transplanted in CR2 tend to experience inferior survival compared with those in CR1. We retrospectively investigated the impact of pretransplant variables on the outcome of patients transplanted with AML in CR2. Ninety-four patients with AML in CR2 received a transplant between 1999 and 2011 with myeloablative (MA, n ¼ 65) or reduced-intensity conditioning regimens (RIC, n ¼ 29). Variables investigated included cytogenetic risk at diagnosis (SWOG), hematopoietic cell transplantation-specific comorbidity index (HCT-CI), CMV status, duration of CR1 and age. Median age of all patients was 47 years (range 18-70). Multivariable analysis for OS identified three prognostically significant categories: a favorable risk group included patients with duration of CR1 X6 months, age o55 years and HCT-CI score 0-3, an intermediate risk group with duration of CR1 X6 months, age o55 years and HCT-CI score 4-5 and a high-risk group with duration of CR1 o6 months or age X55 years (P ¼ 0.0001) with 5-year survivals of 53%, 31% and 6%, respectively. Acute and chronic GVHD did not influence this risk stratification. The stated risk factors discriminate patients with different OS and may assist in decision making for allo-SCT.
INTRODUCTION
Allo-SCT is potentially curative for patients with AML. 1 The beneficial role of allo-SCT compared with non-transplant strategies was documented in several trials that are included into meta-analyses 2,3 for patients with intermediate or unfavorable cytogenetics transplanted in CR1. 4 The outcome data of patients in these less favorable cytogenetic groups rivaled the survival observed in non-transplanted patients with favorable cytogenetic risk. Over the course of the last decade, advances made in the care of transplanted patients have resulted in increased long-term survival due to decreased treatment-related mortality. 5 In recent years, the utilization of reduced-intensity conditioning regimens (RIC) has permitted older patients with AML to undergo allo-SCT. This approach relies on the GVL effect for tumor eradication while reducing early treatment-related mortality. 6 A number of risk scores have been developed to predict the effect of comorbidities and pretransplant variables on outcome. 7, 8 Patients with AML who relapse after conventional therapy have heterogeneous responses to salvage treatment and the role of allo-SCT remains under study. Current information is largely derived from case series that include data for patients transplanted in untreated relapse, refractory disease and patients that achieved a CR2 through salvage therapy. Five-year survival rates of 30-35% are reported. [9] [10] [11] [12] Combining four clinical parameters, Breems et al. 10 constructed a risk assessment tool that demonstrates the heterogeneity of patients with AML in relapse. Patients can be segregated into three distinct categories with respect to their response to different salvage strategies. They demonstrated the superiority of allo-SCT compared with autologous transplants and conventional management for each of the risk categories. Although allo-SCT improves outcome, 12 the benefit is limited particularly in older patients. 13 The question remains whether or not the difference in outcome compared with results observed for patients transplanted in CR1 relates to a difference in disease biology or differences in comorbidity associated with repeated courses of induction chemotherapy. It is the purpose of this retrospective single center cohort study to assess patients in CR2 for the impact of clinical parameters such as karyotype at diagnosis, duration of CR1, age of the recipient, CMV serostatus and coexisting comorbidities on OS, relapse rate (RR) and non-relapse mortality (NRM) and to identify patients that derive the most benefit from transplantation.
PATIENTS AND METHODS Patients
The study population consisted of 94 consecutive patients aged 18-70 years with AML transplanted in CR2 from matched related donors (n ¼ 35) or matched unrelated donors (n ¼ 59), during the time period between 1999 and 2011. Patients were referred to the transplant program at Princess Margaret Hospital after achieving a CR2 following reinduction therapy administered either at the same institution or one of the other treatment centers within the catchment area of the transplant program. Their eligibility for the transplant was evaluated based on established criteria. Patients with previous allo-SCT were excluded. All patients involved in this analysis had given consent for the transplant, as well as access to the transplant-related data. Data were collected from the Electronic Patient Record of the hospital, as well as the Bone Marrow Transplant Program database. Ethics approval was obtained from the research ethics board of the University Health Network/Princess Margaret Hospital.
Data
The data collected and subsequently analysed involved a number of preand post-transplant variables, including age, gender, cytogenetic risk at diagnosis, 14 duration of CR1 and total number of chemotherapy cycles administered before the transplant, as well as the conditioning regimen, hematopoietic progenitor cell source, related or unrelated donor status, donor age and CMV serostatus of donor and recipient.
Moreover, comorbidity and risk scores were calculated and analysed for their effect on survival. These included the Breems score for AML in first relapse, 10 the modified mEBMT score 8 and the hematopoietic cell transplantation-specific comorbidity index (HCT-CI score). 7 Conditioning regimens and GVHD prophylaxis
Patients were conditioned either with myeloablative (MA) or RIC regimens. The latter were reserved for patients aged 60 and above or for younger patients with significant comorbidities.
The 
Definitions of clinical end points
For the purpose of this study, CR2 was defined as achievement of a BM with o5% blasts and count recovery after at least one cycle of reinduction chemotherapy, as well as cerebrospinal fluid negativity. Included are patients with incomplete count recovery but adequate marrow morphology, denoted as CR2i. Relapse was defined as X5% blasts in a BM aspirate or the development of extra-medullary leukemia following transplant. Survival times were measured from the date of allo-SCT until death from any cause. Alive patients were censored on the date of their last follow-up.
Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were diagnosed and graded using established criteria. 15, 16 The date of onset and maximum severity of aGVHD and cGVHD was recorded.
Statistical analysis
Patient demographics and treatment-related outcomes were reported using descriptive statistics. Categorical variables such as gender, donor type, graft source, conditioning chemotherapy regimen intensity and cytogenetic risk category were summarized with counts and percentages. Continuous variables such as donor age, length of CR1 and follow-up duration were summarized with means and/or medians with ranges. Data were updated as of June 2012.
The main outcome variables of interest include death due to any cause (OS), RR and NRM. The time to event was calculated in months from the date of BMT to the date of event or last date of patients known to be alive. OS was calculated using the Kaplan-Meier product-limit method. The logrank test was used as a univariate analysis to compare levels of all the potential variables of interest. Relapse was considered as competing risk for NRM. Cumulative incidence of NRM was calculated using competing risk analysis, as suggested by Pepe and Mori. 17 For disease relapse, outcome was assessed by calculating the RR along with the odds ratio.
Multivariable analysis was performed using Cox proportional hazards regression, to assess the combined effect of covariates considered to influence OS as evaluated by univariate analysis. Finally, binary partitioning was used to characterize cutpoints with optimal statistical resolution. Patients were then grouped based on identified risk effectors and stratified into favorable, intermediate and unfavorable risk for OS. This risk stratification model was tested to assess the influence of the time of transplant during the 12-year enrollment period as a continuous, as well as categorical variable (periods 1999-2003, 2004-2007 and 2008-2011) . To examine whether or not the post-transplant events of aGVHD and cGVHD influenced the predictive value of the model, aGVHD and cGVHD were investigated as time-dependent covariates. Fine and Gray's method for competing risk 18 was applied for NRM. All P-values were two-sided and for the statistical analyses Po0.05 was considered to indicate a significant difference. Data analysis was performed using Statistical Analysis Software (SAS Institute Inc., Cary, NC, USA) Version 9.2, and using R version 2.14.0, the R foundation for statistical computing.
RESULTS

Patient and disease characteristics
Patient and disease characteristics are summarized in Table 1 . Ninety-four patients were transplanted with a median age of 47. Forty-two patients (45%) were male, 24 (26%) were 55 years of age or older. Cytogenetic data at diagnosis were available for sixtyeight patients (72%). Ten patients (15%) belonged to the favorable, 40 (59%) to the intermediate and 15 (22%) to the unfavorable-risk group. The cytogenetic risk of three patients was considered unknown.
14 Of the 35 patients with normal karyotype (intermediate risk), molecular status for FLT3-ITD was available for 18 patients of which 16 patients were FLT3-ITD negative. Nineteen patients (20%) underwent transplant in CR2i with incomplete platelet recovery. Eight patients (9%) had AML secondary to a previous malignancy. Median duration of CR1 was 10.5 months (range 1-80). The median number of chemotherapy cycles per patient was 5 (range 2-8). The percentage of patients with different values of the previously described Breems score is listed in Table 1 .
Transplant-related characteristics Transplant-related characteristics are summarized in Table 1 . Hematopoietic progenitor cell source was BM in 28 (30%) patients and PBSC in 66 (70%) patients. Concerning donor type, matched related donors were used in 35 (37%) patients. Median donor age was 39 years (range 14-73). Seronegativity of both donor and recipient for CMV was observed in 31 (34%) patients.
Conditioning regimens are summarized in Table 1 . Among all patients, 65 (69%) received MA conditioning, of which 39 (41%) recieved the classic regimens (BUCY, CYTBI) and 26 (28%) the more recently adopted FBT400 MA regimen. Twenty-nine patients (31%) recieved RIC, 11 (12%) with the regimens FluTBI, FluBU and 18 recieved the more recently adopted FBT200 RIC regimen.
The percentages of patients for whom the previously described comorbidity and risk scores (HCT-CI, mEBMT) could be determined are listed in Table 1 .
Post-transplant events Post-transplant events are shown in Table 2 . The median follow-up of patients alive was 49 months (range 13-145). Grade II-IV aGVHD rate was 48% (n ¼ 45) while the incidence of cGVHD was 59% (n ¼ 56, cGVHD mild 2%, moderate 38%, severe 19% of all patients). Twenty-three patients (24%) relapsed, at a median of 11.5 months (range 2-81). For the 62 patients that died, cause of death is described in Table 2 .
OS
The results of the univariate analysis of the effect of pretransplant variables on OS are summarized in Table 3 . Univariate analysis identified length of CR1 as the strongest predictor of survival post-transplant. Patients with o6 months CR1 demonstrated the poorest survival (P ¼ 0.0004) (Figure 1 ). The 2-year OS for patients with CR1 o6 months (18 patients) was 22.2% (95% CI: 0.069-0.43) while X6 months (76 patients) was 44.0% (95% CI: 0.33-0.55).
Patients in CR2 vs CR2i demonstrated no significant difference (P ¼ 0.33). Binary partitioning identified the age cutoff X55 vs o55 years as optimal discrimination in terms of increased risk for OS (P ¼ 0.028, HR ¼ 1.83, 95% CI: 1.07-3.14). The HCT-CI score, as originally stratified by Sorror et al., 7 had no significant effect on OS (those with score 0-2 vs 3 or above, P ¼ 0.16). When patients were stratified as those with score 0-3 compared with those with score 4-5, a marginal significance on OS was demonstrated (P ¼ 0.05). The mEBMT score (p3 vs 43) did not demonstrate statistically significant impact (P ¼ 0.43).
Between all MA and all RIC patients no significant difference in OS was seen (P ¼ 0.43). Comparison of the MA regimens demonstrated that patients receiving the previously used classic regimens had a significant survival disadvantage over the newer FBT400 (P ¼ 0.045, HR ¼ 2.05, 95% CI: 1.014-4.161). Two-year OS with the classic regimens was 33.3% while for FBT400 this was 57.7%. Classical RIC regimens compared with the newer FBT200 regimen did not demonstrate statistically significant difference in OS (P40.05). Cytogenetic risk category according to the SWOG/ ECOG criteria (favorable, intermediate, unfavorable) had no significant effect (P ¼ 0.20). Donor type, donor age, graft source, CMV serostatus, the Breems score for first relapse and the number of cycles of chemotherapy until transplant did not demonstrate a significant effect on OS.
Multivariable analysis included the most relevant parameters demonstrated in the univariate analysis for OS (Table 3 ). In the multivariable analysis, duration of CR1 o6 months significantly decreased OS compared with X6 months (P ¼ 0.0008, HR ¼ 2.8, 95% CI: 1.5-5.1). The HCT-CI score demonstrated significant prognostic effect for OS when grouped as scores 0-3 and 4-5 (P ¼ 0.017, HR ¼ 1.95, 95% CI: 1.1-3.4), in favor of the lower score. The recipient age X55 vs o55 years had a marginal effect on OS (P ¼ 0.095, HR ¼ 1.6, 95% CI: 0.9-2.8). On the basis of this analysis, the following risk groups were defined: A favorable risk Group A was composed of patients with CR1 X6 months, age o55 and HCT-CI score 0-3 (41 patients). An intermediate risk Group B contained patients with CR1 X6 months, age o55 and HCT-CI score 4-5 (16 patients). A high-risk Group C (37 patients) included patients with CR1 o6 months, independent of age, as well as patients with CR1 X6 months and age X55 years. A significant difference of the OS distribution between the three risk groups was seen based on log-rank statistics (P ¼ 0.0001) (Figure 2 ; Table 4 ).
The multivariable analysis was repeated by including the year of transplant as a continuous (P ¼ 0.65) as well as a categorical variable (P ¼ 0.34). The predictive value of the model was Months from transplant Overall survival (%) Figure 2 . Kaplan-Meier curve of OS analysis of patients stratified by risk group. Group A: CR1 duration X6 months, age o55 and HCT-CI 0-3 (n ¼ 41). Group B: CR1 duration X6 months, age o55 and HCT-CI 4-5 (n ¼ 16). Group C: CR1 duration o6 months and/or age X55 years (n ¼ 37). Multivariable analysis demonstrated a marginally significant increase in the RR for patients recieving RIC regimens (P ¼ 0.049, odds ratio ¼ 2.7, 95% CI: 1.00-7.36). NRM A total of 42 patients died of causes other than relapse (68% of deaths, Table 2 ). Univariate analysis demonstrated a marginally significantly increase of NRM (P ¼ 0.045, HR ¼ 1.9, 95% CI: 1.01-3.67) for patients with a HCT-CI score of 4-5. Multivariable analysis confirmed the increased risk for NRM in this group (P ¼ 0.048, HR ¼ 1.91, 95% CI: 1.01-3.64). Age X55 (P ¼ 0.448) and the MA regimens (vs all RIC regimens) (P ¼ 0.072) were not significant for NRM.
Association between length of CR1 and cytogenetic risk The previously described categorical variable length of CR1 o or X6 months was tested for association with cytogenetic risk group as defined previously. Fisher's exact test was used to compensate for cytogenetic data missing. This demonstrated a significant difference in distribution of cytogenetic risk (P ¼ 0.0013) with a predominance of high-risk cytogenetics in the CR1 o6 months group.
DISCUSSION
Relapse in patients with AML represents a significant risk factor for poor prognosis of conservatively managed patients. In general, only 5% of these patients survive 45 years. 10, 19 In a large study of almost 667 patients with AML, in first relapse Breems et al. 10 identified risk factors predictive of outcome after salvage therapy with either conventional chemotherapy or allo-SCT and autologous transplants. These included duration of CR1, cytogenetics at diagnosis, age at relapse and previous transplant. The effects were combined to construct a weighted risk score. Allo-SCTs afforded improved disease control and survival compared with conventional treatment. The beneficial effect was seen in all examined risk categories determined by the score. Large-scale studies to investigate the role of allo-SCT in patients with AML in CR2 are not available. Information is largely derived from subset analyses of studies that include patients in both CR1 and CR2. Our retrospective study was designed to examine whether or not the outcome of transplants performed for patients in CR2 can be predicted by disease-related parameters such as cytogenetic risk at diagnosis, duration of remission and comorbidities present at the time of transplant. The outcome measures included OS, RR and NRM. We were able to demonstrate in a multivariable model that the OS after transplantation was influenced by the duration of CR1, comorbidity at transplant and age of the recipient. We also demonstrated that the predictive value of these parameters was not affected by the incidence of aGVHD and cGVHD as a post-transplant variable. The most favorable group comprised younger patients (o55 years), with a low HCT-CI score and duration of first remission of X6 months. These patients demonstrated a 5-year survival of 53%. Patients in the same age group that presented with a high HCT-CI score demonstrated a less favorable survival of 31% at 5 years. Patients with a CR1 of o6 months had the worst prognosis independent of age with a 5-year survival of 6%. A similar poor outcome was seen for patients with CR1 X6 months that were aged X55 years at transplant. The significant difference in survival for these three groups was observed at 1 year post transplant and was sustained during an observation period of 5 years. The negative impact of a short CR1 on OS has been reported by other investigators. 20 In our study their risk of death is almost three times that of patients with a CR1 of X6 months. The RR and NRM post transplant was not significantly affected by the short length of CR1. This observation differs from previous reports, which involved fewer patients. 21 As previously documented 22 unfavorable cytogenetics were associated in our cohort with a short CR1. The predictive role of cytogenetic risk for patients receiving an allograft as salvage therapy remains under debate. Studies by Armand et al., Fung et al., and Ferrant et al., [23] [24] [25] reported an increased RR and worse OS for patients transplanted with unfavorable cytogenetics. Our study demonstrated similar outcomes for patients transplanted in CR2 independent of their cytogenetic risk. This information confirms a previous study by Chalandon et al. 4 with 79 patients with cytogenetics at diagnosis transplanted in CR1. However, both studies are limited due to a small sample size.
A number of comorbidity scores were developed to assist in the evaluation of outcome-determining risk indicators before transplantation. Most widely used is the HCT-CI score published by Sorror et al., although its impact in different scenarios remains unclear as shown by a number of different studies. [26] [27] [28] Our data suggested marginal contribution of the HCT-CI score for recipients of allografts in CR2. Assessment of the impact of pre-existing comorbidities on OS and RR is of particular importance for older transplant recipients that are usually prepared with RIC regimens 10, 13 resulting in a higher RR. [29] [30] [31] [32] The association between age and comorbidity became apparent in our study by comparing the outcomes of the three risk groups defined above. Although the number of patients in this study is relatively small and the interval during which the transplants were performed extends over 12 years, parameters were identified that discriminate patients with significant differences in their risk profile before transplantation. The small number of patients, the extended enrollment period and changes in the management during this time interval have to be taken into account in the interpretation of the presented data. We addressed these concerns by testing the validity of the risk score model using the year of the transplant as a continuous, as well as a categorical variable. Both analyses demonstrated that the risk model performed independently of the time of transplantation. Its application is particularly helpful in older patients to assist in the evaluation and decision process whether or not to proceed with an allograft.
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